Regeneron Pharmaceuticals (REGN) Proxy filing summary

Executive summary

• Achieved $14.3B in 2025 revenues, with four blockbuster medicines and nearly 50 clinical candidates in development across six therapeutic areas.

• Invested $5.9B in R&D in 2025 (~41% of revenues), with $6.6B anticipated for 2026; $9B committed to U.S. manufacturing and R&D expansion.

• Returned $3.8B to shareholders in 2025 via share repurchases and dividends; initiated a quarterly cash dividend program.

• Achieved or exceeded nearly all 2025 responsibility goals and launched new 2030 ESG targets.

• Maintained an industry-leading 93% employee retention rate in 2025.

Voting matters and shareholder proposals

• Election of five directors for a one-year term.

• Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026.

• Advisory vote to approve executive compensation (say-on-pay).

Board of directors and corporate governance

• Board declassification approved in 2025, phasing in annual elections by 2028.

• Established a new Digital Technology Committee in April 2026 to oversee digital strategy, AI, and cybersecurity.

• Enhanced board committee membership and added new directors with diverse expertise.

• 85% of directors are independent; six of 13 directors are National Academy of Sciences members, including two Nobel laureates.

• Lead Independent Director role strengthened; annual board and committee self-evaluations conducted.